<DOC>
	<DOCNO>NCT02071758</DOCNO>
	<brief_summary>The purpose study compare safety , tolerability , immunogenicity healthy adult subject investigational vaccine develop prevention visceral leishmaniasis .</brief_summary>
	<brief_title>Phase 1 LEISH-F3 + SLA-SE Vaccine Trial Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males females 18 49 year age . Must good general health confirm medical history physical exam . Female subject must negative serum pregnancy test screen negative urine pregnancy test day study vaccination , must breastfeed , require use one follow method contraception first 3 month study : hormonal ( e.g. , oral , transdermal , intravaginal , implant , injection ) ; double barrier ( i.e. , condom , diaphragm spermicide ) ; intrauterine device ( IUD ) system ( IUS ) ; vasectomize partner ( 6 month minimum ) ; abstinence ; bilateral tubal ligation ( conception postprocedure ) . These precaution necessary due unknown effect LEISHF3 + SLASE LEISHF3 + GLASE might cause fetus newborn infant . The follow screening laboratory value must within normal range clinically significant determine PI Medical Monitor ( MM ) : sodium , potassium , BUN , ALT , AST , total bilirubin , alkaline phosphatase , creatinine , fast glucose , total WBC count , hemoglobin , platelet count . The following serology test must negative : HIV 1/2 antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody . Negative urine test recreational drug alcohol per Clinical Research Unit standard . Urinalysis clinically significant determine study clinician . Must capable completing study memory aid English . Must give informed consent , able willing make evaluation visit , reachable telephone personal contact study site personnel , permanent address . History possible infection Leishmania previous exposure Leishmania vaccine experimental product contain SLA GLA . Veterans serve military Middle East ( Iran , Iraq ) , Afghanistan , area endemic Leishmania . Travelers , immigrant , area endemic Leishmania . Participation another experimental protocol receipt investigational product within past 3 month . Treatment immunosuppressive drug ( e.g. , oral injected steroid , prednisone ; high dose inhaled steroid ) cytotoxic therapy ( e.g. , chemotherapy drug radiation ) within past 6 month . Received blood transfusion within past 3 month . Donated blood product ( platelet , whole blood , plasma , etc . ) within past one month . Received vaccine within past 1 month plan immunization study exception seasonal influenza vaccine give Day 084 Day 138168 due 30day washout period prior immunology blood draw . History autoimmune disease cause immunosuppressive state . History evidence acute chronic illness ( include cardiovascular , pulmonary , neurological , hepatic , rheumatic , hematological , metabolic , renal disorder , control hypertension ) , use medication , opinion Principal Investigator , may interfere evaluation safety immunogenicity vaccine . Rash , tattoo , dermatological condition could adversely affect vaccine injection site interfere evaluation . BMI , opinion Investigator , pose health risk . Hypertension ( systolic &gt; 150 diastolic &gt; 95 ) . History significant psychiatric illness current use medication . Known suspected alcohol drug abuse within past 6 month . Chronic smoker ( &gt; 20 pack year ) . Subjects history previous anaphylaxis severe allergic reaction vaccine , egg , unknown allergen . Subjects unlikely cooperate requirement study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Leishmaniasis</keyword>
	<keyword>Visceral leishmaniasis</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>GLA</keyword>
	<keyword>SLA</keyword>
</DOC>